Ex-Biocon CEO Siddharth Mittal Takes Charge as Syngene MD & CEO

Syngene International has appointed Siddharth Mittal as its new Managing Director and Chief Executive Officer, effective July 1, 2026. He succeeds Peter Bains, whose tenure concluded on June 30, ushering in a new phase of leadership for one of India’s leading contract research, development, and manufacturing organizations (CRDMOs).

Mittal joins Syngene with nearly three decades of experience in the pharmaceutical and biotechnology industry. Prior to this appointment, he spent 13 years at Biocon, where he progressed from Chief Financial Officer to Managing Director and Chief Executive Officer. During his leadership, he played a pivotal role in driving business growth, securing key regulatory approvals, expanding international operations, and commercializing Biocon’s GLP-1 portfolio across global markets.

At Syngene, Mittal’s immediate priorities include strengthening commercial execution, enhancing delivery excellence, improving cost competitiveness, and restoring growth momentum. He also aims to build on the company’s strong scientific capabilities while reinforcing its position as a preferred global CRDMO partner for pharmaceutical and biotechnology companies.

The leadership transition comes at a significant time for Syngene as demand for integrated research, development, and manufacturing services continues to rise worldwide. The company has been expanding its biologics manufacturing capacity, investing in advanced scientific capabilities, and strengthening partnerships with leading global pharmaceutical companies to support innovation across the drug development lifecycle.

With Siddharth Mittal at the helm, Syngene is expected to sharpen its commercial strategy, enhance operational execution, and accelerate long-term growth while continuing to deliver world-class scientific solutions to customers across the global life sciences ecosystem.